Diethyltryptamine

Diethyltryptamine (DET), also known as N,N-diethyltryptamine or T-9, is a psychedelic drug of the tryptamine family closely related to dimethyltryptamine (DMT).<ref name="TiHKAL">Template:CiteTiHKAL https://www.erowid.org/library/books_online/tihkal/tihkal03.shtml</ref> It is taken orally, but can also be used by parenteral routes.<ref name="TiHKAL" />

The drug acts as a non-selective serotonin receptor agonist, including of the serotonin 5-HT_2A receptor among others.<ref name="Blough_2014" /><ref name="Kozell_2023" /> It has not been found to occur endogenously.<ref name="Gartz_1989">Template:Cite journal</ref> DMT is a close structural homologue of DMT and dipropyltryptamine (DPT).<ref name="TiHKAL" /> Other analogues of DET include 4-HO-DET (ethocin), ethocybin (4-PO-DET), and 5-MeO-DET.<ref name="TiHKAL" />

DET was first synthesized in 1956 by Stephen Szára and subsequently described in material published in 1957.<ref name="Szara_1957">Template:Cite book</ref> More systematic studies were reported later by Szára and colleagues<ref name="Szara_1966">Template:Cite journal</ref> and independently by Böszörményi and colleagues.<ref name="Boszormenyi_1959">Template:Cite journal</ref>

Use and effects

According to Alexander Shulgin in his book TiHKAL (Tryptamines I Have Known and Loved), DET's dose range is 50 to 100Template:Nbspmg orally and its duration is 2 to 4Template:Nbsphours.<ref name="TiHKAL" /><ref name="Malaca_2020" /> It was also assessed at oral doses of 44 to 400Template:Nbspmg, though 150Template:Nbspmg was described as "a little too much" and the 400Template:Nbspmg dose was simply described as "too high".<ref name="TiHKAL" /> Its onset is 40Template:Nbspminutes to more than 1Template:Nbsphour and peak effects occurred at just over 1Template:Nbsphour.<ref name="TiHKAL" /> In addition to oral administration, DET was assessed by smoking at doses of 40 to 90Template:Nbspmg, by subcutaneous injection at a dose of 40Template:Nbspmg, by intramuscular injection at a dose of 60Template:Nbspmg, and by intravenous injection at a dose of 60Template:Nbspmg.<ref name="TiHKAL" /><ref name="Halberstadt_2020">Template:Cite journal</ref> By these routes, it has a faster onset than when taken orally.<ref name="TiHKAL" /> The drug is said to taste terrible when smoked, like "burning plastic".<ref name="TiHKAL" /> DET was initially assumed to be inactive orally similarly to dimethyltryptamine (DMT), but this proved to be incorrect.<ref name="TiHKAL" />

The effects of DET have been reported to include similar "illusions" and hallucinations" as DMT, a wave-like time course of effects, closed-eye visuals, open-eye visuals, auditory and olfactory hallucinations, synesthesia, feeling like in another world, cosmic thinking, mystical and philosophical feelings, dream-like mysteriousness of objects, greater emotional significance of objects, peoples' faces seeming "mask-like", enhanced appreciation of art, architecture, and music, feeling like a small child perceiving the world and discovering it anew, time dilation, enjoyment and euphoria, increased empathy, and emotional insights.<ref name="TiHKAL" /><ref name="Malaca_2020">Template:Cite journal</ref><ref name="Szara_1966" /> Additional effects included feeling stoned, alcohol-like intoxication, drifting of thoughts, and difficulty concentrating and cognitive impairment.<ref name="TiHKAL" /><ref name="Szara_1966" /> The effects of the drug were described as highly dependent on set and setting, with prominent negative reactions in unfavorable environments or with too high of doses, including unpleasantness, anxiety, paranoia, social withdrawal, and unwillingness to take the drug again, among others.<ref name="TiHKAL" /><ref name="Szara_1966" /> Physical effects of DET included DMT-like vegetative or autonomic symptoms, pupil dilation, sweating, slight burning and numbness of hands and feet, dizziness, vertigo, feeling sick, paleness, shakiness, muscle tremors, athetoid movements, vomiting, feeling of hollowness in the chest, pronounced tachycardia, pressor effects, and other somatic symptoms.<ref name="TiHKAL" /><ref name="Malaca_2020" /><ref name="Szara_1966" /> Subsequent-day effects included an afterglow, hangover, lassitude, and cognitive fuzziness.<ref name="TiHKAL" />

Pharmacology

Pharmacodynamics

Template:Nowrap

Target	Affinity (Ki, nM)
5-HT1A	370 (Ki) 138 (Template:Abbrlink) 98% (Template:Abbrlink)
5-HT2A	530 (Ki) 68–612a (Template:Abbr) 46a–90% (Template:Abbr)
5-HT2C	970 (Ki) 660a (Template:Abbr) 106%a (Template:Abbr)
Template:Abbrlink	1,200 (Ki) 254–258 (Template:Abbr)
Template:Abbrlink	>10,000 (Template:Abbr)
Template:Abbrlink	>10,000 (Template:Abbr)
Notes: The smaller the value, the more avidly drug interacts with the site. Footnotes: a = Stimulation of Template:Abbrlink formation. Sources: <ref name="Blough_2014">Template:Cite journal</ref><ref name="Kozell_2023">Template:Cite journal</ref>

Similarly to other classic psychedelics, DET acts as a non-selective serotonin receptor agonist, including of the serotonin 5-HT_2A, 5-HT_2B, and 5-HT_2C receptors.<ref name="Blough_2014" /><ref name="Kozell_2023" /><ref>Template:Cite journal</ref> The drug has been shown to activate G_q-mediated signaling at the serotonin 5-HT_2A receptor with E_max higher than 70%<ref name="Wallach_2023">Template:Cite journal</ref> and to produce the head-twitch response in rodents which is a behavioral proxy of psychedelic-like effects.<ref name="Halberstadt_2020" /><ref name="Wallach_2023" />

DET is a very weak reversible monoamine oxidase inhibitor (MAOI), with Template:Abbrlink values of 59Template:NbspμM for serotonin and 5,000Template:NbspμM for tryptamine as substrates.<ref name="Huszti_1964" /> Injections of 30Template:Nbspmg/kg to rats resulted in 67% reduction of brain MAO-A activity 15Template:Nbspminutes after administration.<ref name="Huszti_1964">Template:Cite journal</ref> The substance may also act as a serotonin reuptake inhibitor, with low affinity but moderate potency.<ref name="Kozell_2023" /> It shows no activity as a norepinephrine or dopamine reuptake inhibitor.<ref name="Kozell_2023" />

Pharmacokinetics

DET demonstrates significant resistance to metabolism by monoamine oxidase A (MAO-A) compared to DMT. This may be due to the increased steric bulk of the N-ethyl substituents relative to the respective methyl groups of DMT which results in metabolic stability sufficient for oral activity.<ref name="Huszti_1964" /><ref name="US20240286998">Template:Cite patent</ref> This is also true for many other tryptamines with larger nitrogen substituents.<ref name="TiHKAL" />

The drug similarly to DMT is rapidly absorbed from the intraperitoneal cavity and quickly distributed through plasma, liver and brain. Most of the substance had disappeared from the aforementioned tissues 30Template:Nbspminutes from administration, except in the brain, where it could still be detected at 60Template:Nbspminutes.<ref name="Huszti_1964" />

Likewise to DMT the substance is metabolized through 6-hydroxylation and N-dealkylation to form the corresponding intermediates.<ref name="Szara_1968">Template:Cite book</ref> These metabolites were found to be excreted in urine of about 20% of the administered dose as the glucoronide conjugate, of which the parent compound can be detected by chromatographic analysis at low concentrations (3–5%). Hepatic 6-hydroxylation of the indole ring, yields a minor, psychoactively inactive metabolite 6-hydroxy-DET (6-HO-DET) in similar concentration, with additional hydroxylation possible at alternative positions. Repeated administration of DET, or second exposure one to two weeks after the first, resulted in significant metabolic changes. The unchanged drug excreted after a later exposure was significantly lower, while the excretion of the metabolites which were measured in this case were higher than at the first exposure to DET.<ref name="Szara_1966" /><ref name="Szara_1968" />

Chemistry

DET, also known as N,N-diethyltryptamine, is a synthetic compound in the tryptamine class, structurally related to the endogenous neurotransmitter serotonin and the naturally occurring psychedelic compounds dimethyltryptamine (DMT) and dipropyltryptamine (DPT). It is the ethyl analogue of DMT.<ref name="Malaca_2020" />

Synthesis

The chemical synthesis of DET has been described.<ref name="TiHKAL" /><ref>Template:Cite journal</ref><ref>Template:Cite journal</ref>

Analogues

Analogues of DET include dimethyltryptamine (DMT), dipropyltryptamine (DPT), methylethyltryptamine (MET), methylpropyltryptamine (MPT), ethylpropyltryptamine (EPT), 4-HO-DET, 5-HO-DET, 6-HO-DET, 4-AcO-DET, ethocybin (4-PO-DET or CEY-19), 6F-DET, and 2-Me-DET.<ref name="TiHKAL" />

History

DET was first synthesized and administered intramuscularly in a 60Template:Nbspmg dose by Stephen Szára in 1956. It was subsequently described in his material published in 1957.<ref name="Szara_1957" /> More systematic studies were reported later by Szara and colleagues and independently by Böszörményi and colleagues.<ref name="Boszormenyi_1959" /><ref name="Szara_1966" /> Early research began as a search for “psychosis mimics” in psychiatry, then expanded into broader psychedelic and structure–activity studies. Selection of study subjects for some of these studies was criticized by Alexander Shulgin in his 1997 book TiHKAL (Tryptamines I Have Known and Loved) for its "oppressive research environment".<ref name="TiHKAL" /> For many years, based on early clinical reports and private communications, Shulgin maintained that DET exhibited psychoactive effects only when administered via parenteral routes. He eventually revised his view, ultimately acknowledging that the substance is also orally active.<ref name="TiHKAL" />

Initially, DET was not classified as a controlled substance, and some early clinical and experimental psychopharmacological research used it without scheduling restrictions. By the late 1960s and early 1970s, however, increasing regulatory attention led to tighter controls and this led to DET getting placed in Schedule I internationally by the Convention on Psychotropic Substances.<ref name="Board_2003" />

Modern research on DET remains limited compared to dimethyltryptamine (DMT), due to its status as a controlled substance and the predominance of focus on other tryptamines with greater prevalence in traditional or clinical contexts. Most recent studies and reviews refer to DET primarily in comparative molecular pharmacology, assessing its receptor binding and signaling at serotonin receptors.<ref name="Blough_2014" /><ref name="Kozell_2023" />

Society and culture

Legal status

International

DET is listed under Schedule I of the United Nations 1971 Convention on Psychotropic Substances, placing it under international control.<ref name="Board_2003">Template:Cite web</ref> This means that countries that are parties to the Convention are required to regulate DET production, distribution, and use, restricting it to scientific and very limited medical purposes. Possession and trade of DET without appropriate authorization is prohibited under international law.

Australia

DET is considered a Schedule 9 prohibited substance in Australia under the Poisons Standard (October 2015).<ref name="Poisons Standard">Template:Cite web</ref> A Schedule 9 substance is a substance which may be abused or misused, the manufacture, possession, sale or use of which should be prohibited by law except when required for medical or scientific research, or for analytical, teaching or training purposes with approval of Commonwealth and/or State or Territory Health Authorities.

Germany

DET is controlled under Anlage I BtMG (Narcotics Act, Schedule I).<ref>Template:Cite web</ref> as of January 24, 1974.<ref>Template:Cite web</ref> It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.<ref>Template:Cite web</ref>

Italy

DET is a Schedule I controlled substance.<ref>Template:Cite web</ref>

New Zealand

DET is a Class A controlled substance in New Zealand.<ref>Template:Cite web</ref>

Switzerland

DET is a controlled substance specifically named under Verzeichnis D.<ref>Template:Cite web</ref>

United Kingdom

DET is a Class A controlled substance.<ref>Template:Cite web</ref>

United States

DET is a Schedule I controlled substance.<ref>Template:Cite web</ref>

Research

Psychosis model

Early studies of DET as well as other psychedelics were focused on their presumed psychotomimetic properties.<ref name="titlePSILOCYBIN AND DIETHYLTRYPTAMINE: TWO TRYPTAMINE HALLUCINOGENS">Template:Cite journal</ref> Researchers theorized that abnormal metabolites of endogenous chemicals such as tryptamine, serotonin, and tryptophan could be the explanation for mental disorders such as schizophrenia, or psychosis.<ref name="Khazan_1965">Template:Cite journal</ref> DET, along with other synthetic psychedelics, was administered to both patients and healthy volunteers to understand its effects and as a possible biological model for psychosis. With the progression of science and pharmacological understanding, this belief has been dismissed by most researchers.<ref>Template:Cite journal</ref><ref>Template:Cite journal</ref>

Mushroom production

Although DET is a synthetic compound with no known natural sources, it has been used in conjunction with the mycelium of Psilocybe cubensis to biosynthetically produce the chemicals ethocybin (4-PO-DET) and ethocin (4-HO-DET). Isolation of the alkaloids resulted in 3.3% ethocybin and 0.01-0.8% ethocin.<ref name="Gartz_1989" />

See also

• Substituted tryptamine

External links

• DET - Isomer Design
• DET - PsychonautWiki
• DET - Erowid
• DET - TiHKAL - Erowid
• DET - TiHKAL - Isomer Design
• The Modest & Dandy DET thread - Bluelight

Template:Psychedelics Template:Serotonin receptor modulators Template:Monoamine reuptake inhibitors {{#invoke:Navbox|navbox}}